Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05493059
Other study ID # 2022_028
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 8, 2022
Est. completion date October 8, 2022

Study information

Verified date August 2022
Source Centre Hospitalier de Cayenne
Contact Romain BLAIZOT
Phone +594 594 39 53 59
Email romain.blaizot@ch-cayenne.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Miltefosine is the only oral treatment currently available for Cutaneous Leishmaniasis. Despite several reports of good efficiency in other countries of South America, miltefosine remains limited to a compassionate use in France. The objective of this study is to collect data regarding the efficacy, safety and acceptability of miltefosine in patients treated in French Guiana since 2017.


Description:

In French Guiana, Cutaneous Leishmaniasis is mostly caused by Leishmania guyanensis (80% of cases), followed by L. braziliensis (10%) and rarer species. L. guyanensis is usually treated with a single injection of pentamidine. However, pentamidine-resistant infections (10%) and all L. braziliensis are treated with either amphotericine B or meglumine antimoniate. These treatments can only be used during an hospitalization, which is the source of important indirect costs and discomforts for patients from the remote areas of French Guiana. Miltefosine is the only oral treatment available for Cutaneous Leishmaniasis. While it is widely used in South America (with good reported efficacy), the data available in France are scarce. This treatment, if available on a larger scale in France, would allow a treatment without hospitalization, which would be very suitable for French Guianese patients. Our objective is to collect data on patients already treated with miltefosine in French Guiana (current indications being failure, side effect or impossible delivery of amphotericine B and meglumine antimoniate) in order to assess its efficacy, safety and acceptability. Patients treated with miltefosine at the Cayenne Hospital Center between 2017 and 2022 will be contacted by phone so as to answer questions regarding their quality of life during the infection and their satisfaction concerning miltefosine as a treatment. Data on their symptoms and general informations will be extracted from the medical files. Primary objective: To assess the efficacy, tolerance and acceptability of Miltefosine among patients already treated with this drug as part of its AAC in French Guiana. Observational, retrospective and prospective, monocentric study Research Involving Human Person Category 3 (RIPH3) - Non-Interventional (RNI) - Questionnaire (Jardé Law)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date October 8, 2022
Est. primary completion date August 8, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Mucocutaneous Leishmaniasis proven by culture and/or polymerase chain reaction (PCR) - Seen in French Guiana between 01/01/2017 and 01/04/2022, in dispensaries (CDPS) or in the Dermatology Department of the CHC - Having received treatment with Miltefosine - Patient who consented to participate in the study - Age equal or superior to 18 years Exclusion Criteria: - Clinically suspected but not parasitologically proven leishmaniasis - Refusal to participate - Age < 18 - Patient under legal guardianship

Study Design


Intervention

Other:
Data collection
o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
Questionnaires
o Administration of two standardized questionnaires by telephone in prospective: Dermatology Life Quality Index (DLQI) Treatment Satisfaction Questionnaire for Medication (TSQM)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier de Cayenne

Outcome

Type Measure Description Time frame Safety issue
Primary Disappearance of any lesion without the appearance of a new lesion, 6 months from the start of treatment with miltefosine The primary endpoint will be therapeutic success, defined as the disappearance of any lesion without the appearance of a new lesion, 6 months from the start of treatment with miltefosine. baseline
Secondary Proportion of treatment-emergent adverse events occurring during treatment Proportion of treatment-emergent adverse events occurring during treatment, categorized as follows: non-symptomatic laboratory abnormalities (mild); symptoms not leading to discontinuation or modification of treatment (moderate intensity); symptoms leading to discontinuation or dose reduction (severe intensity) baseline
Secondary Patients' acceptability of treatment assessed after completion of treatment Patients' acceptability of treatment assessed after completion of treatment, by Treatment Satisfaction Questionnaire for Medication (TSQM) administered by telephone baseline
Secondary Impact of Cutaneous Leishmaniasis on quality of life Impact of Cutaneous Leishmaniasis on quality of life, assessed retrospectively by Dermatology Life Quality Index (DLQI) questionnaire administered by telephone baseline
See also
  Status Clinical Trial Phase
Completed NCT03224858 - Ambulatory ICU Study for Medically and Socially Complex Patients N/A
Completed NCT03663075 - Effect of Group Education and Individual Counselling on Mental Health and Quality of Life in 45-60 Year Old Women N/A
Recruiting NCT04151056 - Impact of the Social Determinants of Health in the Central Catalan Region
Recruiting NCT05715151 - Continuous Quality Improvement Cohorts on Advanced Access N/A
Completed NCT01242319 - Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice N/A
Recruiting NCT06155292 - Report Cards and Feedback for PCCE N/A
Completed NCT02955433 - The Impact of Rideshare Transportation Services on Appointment Adherence N/A
Completed NCT02266069 - PROject - Supportive and Palliative Care and INnOvation - Antwerp (Pro-Spinoza) N/A
Recruiting NCT04702711 - Experiences of Anger in Patients in Primary Health Care With Symptoms of Generalized Anxiety
Completed NCT04521816 - PIM 2.0: Patient Aligned Care Team (PACT) Intensive Management (PIM) Project N/A
Recruiting NCT05709860 - An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy N/A
Completed NCT05121688 - Effectiveness of a Physical Therapy Telerehabilitation Program in Long Post COVID-19 Symptoms in Primary Health Care. N/A
Completed NCT05329246 - Validation of PMcardio AI-assisted Clinical Assistant in Primary Care N/A
Completed NCT02953925 - National-wide Survey on Primary Health Care in China N/A
Completed NCT03100526 - Patient Aligned Care Team (PACT) Intensive Management (PIM) Project N/A
Active, not recruiting NCT04585191 - Reducing Treatment Risk in Older Adults With Diabetes N/A
Recruiting NCT05609981 - Optimising Medication With Focus on Deprescribing in Frail Older People With Multidose Drug Dispensing Systems N/A
Completed NCT04688359 - Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM N/A
Withdrawn NCT04010136 - Identification of Elderly Patients in Need of Palliative Care by Family Physicians N/A
Completed NCT04237883 - Primary Care Clinical Excellence Incentive Study N/A